Sanofi (NYSE:SNY) reported earnings from the quarter that were below analyst expectations, driven (in part) by a strong euro and currency conversion issues. That said, there were other disappointments as well -- Lantus, Sanofi's flagship insulin product, was up 13.5% in constant currencies to just under 1.5 billion euros, a little lighter than analysts had anticipated.
Nonetheless, Sanofi's management is guiding for 4% to 7% revenue growth (at constant currencies) over the next year, driven by several potential exciting pipeline candidates, including U-300 and alirocumab.
In this segment from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass break down the earnings and what investors should watch for moving forward at Sanofi.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
3 Top Value Stocks to Buy in 2018
Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.